Metabolism of 3′-deoxy-3′-[F-18]fluorothymidine in proliferating A549 cells: Validations for positron emission tomography

Nuclear Medicine and Biology

Volumn 31, Issue 7, 2004, Pages 829-837

  Grierson, John R ^a   Schwartz, Jeffery L ^a   Muzi, Mark ^a   Jordan, Robert ^a   Krohn, Kenneth A ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

DNA salvage pathway; FLT; Fluorothymidine; Nucleoside metabolism; PET

Indexed keywords

2' ARABINOFLUORO 5 IODO 2' DEOXYURIDINE; 3' DEOXY 3' FLUOROTHYMIDINE F 18; DEOXYNUCLEOTIDASE; DEOXYURIDINE DERIVATIVE; DNA; ISOENZYME; NUCLEOTIDE; NUCLEOTIDE DERIVATIVE; NUCLEOTIDE DIPHOSPHATE KINASE; PHOSPHOTRANSFERASE; THYMIDINE DERIVATIVE; THYMIDINE KINASE 1; UNCLASSIFIED DRUG; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; 3' FLUOROTHYMIDINE; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ARTICLE; DEGRADATION KINETICS; DRUG METABOLISM; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PHOSPHORYLATION; POSITRON EMISSION TOMOGRAPHY; RADIOACTIVITY; TUMOR GROWTH; VALIDATION PROCESS; ADENOCARCINOMA; CANCER STAGING; CELL PROLIFERATION; EVALUATION; KINETICS; LUNG TUMOR; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; PATHOLOGY; SCINTISCANNING; TUMOR CELL LINE; VALIDATION STUDY;

ADENOCARCINOMA; CELL LINE, TUMOR; CELL PROLIFERATION; DIDEOXYNUCLEOSIDES; HUMANS; KINETICS; LUNG NEOPLASMS; METABOLIC CLEARANCE RATE; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 4644361597     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2004.06.004     Document Type: Article

References (50)

1. Vesselle H., Grierson J., Muzi M., et al. In-vivo validation of [F-18]FLT (3′deoxy-3′-fluorothymidine) as a proliferation imaging tracer in humans: correlation of FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res. 8:2002;3315-3323
2. 18F]fluorothymidine-positron emission tomography for the noninvasive assessment of proliferation in pulmonary nodules. Cancer Res. 62:2002;3331-3334
3. 18F- Fluorothymidine radiation dosimetry in human imaging studies. J Nucl Med. 44:2003;1482-1488
4. 18F]fluoro-2-deoxy-D-glucose in positron emission tomography of colorectal cancer. Eur J Nucl Med Mol Imag. 30:2003;998-1004
5. 18F]FLT PET for diagnosis and staging of thoracic tumours. Eur J Nucl Med Mol Imag. 30:2003;1407-1412
6. 18F]FLT) as positron emission tomography tracer for imaging proliferation in a murine B-cell lymphoma and in human disease. Cancer Res. 63:2003;2681-2687
7. Berthel H., Cleij M.C., Collingridge D.R., et al. 3′-Deoxy- 3′-[18F]fluorothymidine as a marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res. 63:2003;3791-3798
8. 18FLT utilization for colorectal cancer. Eur J Nucl Med Mol Imag. 31:2004;169-178
9. Grierson J.R., Shields A.F. Radiosynthesis of 3′-deoxy-3′-[F- 18]fluorothymidine: [F-18]FLT for imaging cellular proliferation in vivo. Nucl Med Biol. 27:2000;143-156
10. Shields A.F., Grierson J.R., Dohmen B.M., et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nature Med. 4:1998;1334-1336
11. Munch-Petersen B., Cloos L., Tyrsted G., et al. Diverging substrate specificity of pure human thymidine kinases 1 and 2 against antiviral dideoxynucleosides. J Biol Chem. 266:1991;9032-9038
12. Kornberg A, Baker TA. Biosynthesis of DNA precursors. In: DNA Replication, 2nd Ed. New York: Freeman; 1992, pp. 53-100
13. Sherley J.L., Kelly T.J. Regulation of human thymidine kinase during the cell cycle. J Biol Chem. 263:1998;8350-8358
14. Kong X.-B., Zhu Q.-Y., Vidal P.M., et al. Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3′-fluoro-3′-deoxythymidine and 3′-azido-3′-deoxythymidine. Antimicrob Agents Chemother. 36:1992;808-818
15. Sundseth R., Joyner S.S., Moore J.T., et al. The anti-human immunodeficiency virus agent 3′-fluorothymidine induces DNA damage and apoptosis in human lymphblastoid cells. Antimicrob Agents Chemother. 40:1996;331-335
16. Langen P., Etzold G., Hintsche R., et al. 3′-Deoxy-3′- fluorothymidine, a new selective inhibitor of DNA synthesis. Acta Biol Med Ger. 23:1969;759-766
17. Matthes E., Lehmann C., Scholz D., et al. Phosphorylation, anti-HIV activity and cytotoxicity of 3′-fluorothymidine. Biochem Biophys Res Com. 153:1998;825-831
18. Rasey J.S., Grierson J.R., Wiens L.W., et al. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 cells. J Nucl Med. 43:2002;1210-1217
19. Kang S.H., Cho M.J. Biological activity and phosphorylation of 2′-azido-2′-deoxyuridine and 2′-azido-2′-deoxycytidine. Nucleosides Nucleotides. 17:1998;1077-1088
20. Weber G., Nagi M., Natsumeda Y., et al. Regulation of de novo and salvage pathways in chemotherapy. Adv Enz Reg. 31:1995;45-67
21. Feinendegen L.E., Bond V.P., Huges W.L. Physiological thymidine reutilization in rat bone marrow. Proc Soc Exp Biol Med. 122:1996;448-455
22. Cass CE, Young JD, Baldwin SA, et al. Nucleoside transporters of mammalian cells. In: Membrane Transporters as Drug Targets. New York: Kluwer Acedemic/Plenum, 1999, pp. 313-51
23. Plagemann P.G.W., Richey D.P., Zylka J.M., et al. Thymidine transport by Novikoff rat hepatoma cells synchronized by double hydroxyurea treatment. Exptl Cell Res. 83:1974;303-310
24. Hopwood L.E., Dewey W.C., Hejny W. Transport of thymidine during the cell cycle in mitotically synchronized CHO cells. Exptl Cell Res. 96:1975;425-429
25. Damaraju V.L., Damaraju S., Young J.D., et al. Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy. Oncogene. 22:2003;7524-7536
26. Young J.D., Cheeseman C.I., Mackey J.R., et al. Molecular mechanisms of nucleoside and nucleoside drug transport. Cur, Top Membr. 50:2001;329-378
27. Yoa S.Y.M., Ng A.M.L., Sundaram M., et al. Transport of antiviral 3′-deoxy-nucleoside drugs by recombinant human and rat equilibrative, nitrobenzylothioinosine (NMMPR)-insensitive (ENT2) nucleoside transporter proteins produced in Xenopus oocytes. Mol Membr Biol. 18:2001;161-167
28. Guo Y., Kotova E., Chen Z.S., et al. MRP8, ATP-binding cassette C11 (ABCC11), is a cyclic nucleotide efflux pump and a resistance factor for fluoropyrimidines 2′,3′-dideoxycytidine and 9′-(2′- phosphonylmethoxyethyl)adenine. J Biol Chem. 278:2003;29509-29514
29. He Q.M., Skog S., Welander I., et al. Enzyme kinetics of thymidine kinase isoenzymes of Ehrlich ascites tumour. Anticancer Res. 10:1990;1257-1263
30. Skladanowski A.C., Hoffmann C., Krass J., et al. Structure-activity relationship of cytoplasmic 5′-nucleotidase substrate sites. Biochem J. 31:1996;1001-1007
31. Garvey E.P., Lowen G.T., Almond M.R. Nucleotide and nucleoside analogues as inhibitors ofcytosolic 5′-nucleotidase I from heart. Biochem. 37:1998;9043-9051
32. Gazziola C., Ferraro P., Moras M., et al. Cytosolic high-K (subM)-nucleotidase and 5′(3′)-deoxyribonucleotidase in substrate cycles involved with nucleotide metabolism. J Biol Chem. 276:2001;6185-6190
33. Mansson E., Flordal E., Liliemark J., et al. Down-regulation of deoxycytidine kinase in human leukinic cell lines resistant to cladribidine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance. Biochem Pharmacol. 65:2003;237-247
34. Balzarini J., Aquaro S., Knispel T., et al. Cyclosaligenyl-2′- 3′-didehydro-2′,3′-dideoxythymidine monophosphate: efficient intracellular delivery of d4TMP. Mol Pharmacol. 58:2000;928-935
35. Stryer L. Biochemistry. 4th Ed:1995;Freeman, New York
36. Van Rompay AnR, Johansson M., Karlsson A. Phosphorylation of nucleosides and nucleoside analogs by mammalian nucleoside monophosphate kinases. Pharmacol Therap. 87:2000;187-198
37. Huang S.H., Tang A., Drisco B., et al. Human dTMP kinase: gene expression and enzymatic activity coinciding with cell cycle progression and cell growth. DNA Cell Biol. 13:1994;461-471
38. Ostermann N., Segura-Pena D., Meier C., et al. Structures of human thymidylate kinase in complex with prodrugs: implications for the structure-based design of novel compounds. Biochem. 42:2003;2568-2577
39. Eriksson S., Kierdaszuk B., Munch-Petersen B., et al. Comparison of the substrate specificities of human thymidine kinase 1 and 2 and deoxycytidine kinase toward antiviral and cytostatic nucleoside analogs. Biochem Biophys Res Com. 176:1991;586-592
40. Caligo M.A., Cipollini G., Fiore L., et al. NM23 gene expression correlates with cell growth rate and S-phase. Int J Cancer. 60:1995;837-842
41. Gonin P., Xu Y., Milon L., et al. Catalytic mechanism of nucleoside diphosphate kinase investigated using nucleotide analogues, viscosity effects, and x-ray crystallography. Biochem. 38:1999;7265-7272
42. Lacombe M.-L., Milon L., Munier A., et al. The human Nm23/nucleoside diphosphate kinases. J Bioenerg Biomembr. 32:2000;247-258
43. Weber G. Enzymology of cancer cells (first of two parts). N Engl J Med. 296:1977;486-492
44. 11C]-FMAU): a potential nucleoside analog for in vivo study of cellular proliferation with PET. Nucl Med Biol. 22:1995;783-789
45. 14C]FMAU) in rat prostate tumor cells. Nucl Med Biol. 27:2000;361-368
46. Alauddin M.M., Shahinian A., Gordon E.M., et al. Evaluation of 2′-deoxy-2′-fluoro-5-methyl-1-beta-D-arabinofuranosyluracil as a potential gene imaging agent for HSV-tk expression in vivo. Mol Imag. 1:2002;74-81
47. Koehne G., Doubrovin M., Doubrovina E., et al. Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes. Nat Biotechnol. 21:2003;405-413
48. Tjuvajev J.G., Doubrovin M., Akhurst T., et al. Comparison of radiolabeled nucleoside probes (FIAU, FHBG, and FHPG) for PET imaging of HSV1-tk gene expression. J Nucl Med. 43:2002;1072-1083
49. Wang H., Oliver P., Nan L., et al. Radiolabeled 2′- fluorodeoxyuracil-beta-D-arabinofuranoside (FAU) and 2′-fluoro-5- methyldeoxyuracil-beta-D-arabinofuranoside (FMAU) as tumor-imaging agents in mice. Cancer Chemother Pharmacol. 49:2002;419-424
50. Wang J., Eriksson S. Phosphorylation of the anti-hepatitis B nucleoside analog 1-(2′-deoxy-2′-fluoro-1-beta-D-arabinofuranosyl)-5-iodouracil (FIAU) by human cytosolic and mitochondrial thymidine kinase and implications for cytotoxicity. Antimicrob Agents Chemother. 40:1996;1555-1557